ERIC 2022 | Moving towards time-limited treatment in frontline CLL
Florence Cymbalista, MD, Hôpital Avicenne, Bobigny, France, comments on the need to move towards time-limited treatment for patients with chronic lymphocytic leukemia (CLL) in the frontline setting, highlighting some of the toxicities associated with continuous treatment. Prof. Cymbalista additionally outlines some promising time-limited treatment strategies that are currently under investigation, including venetoclax-based combinations or time-limited treatment with a BTK inhibitor with re-treatment upon progression, and various MRD-guided clinical trials. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
